Introduction
Venous thromboembolism (VTE) complicates only 0.05 0.2% of all pregnancies, yet it is a leading cause of maternal morbidity in the western world, while pulmonary embolism (PE) is the cause of about 10% of all maternal deaths during pregnancy and puerperium [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Deep vein thrombosis (DVT) and PE are distinct but related aspects of the disease process called VTE 6, 10 . This is a dynamic process which can be presented as acute form, with all clinical symptoms and signs, and as a silent, subclinical, chronic form, with the recurrence rate of 17.5% during the first two years, and 30.3% within eight years after the first episode 12 . More than 60% of women develop chronic venous insufficiency due to postthrombotic syndrome, with leg swelling, pain, ulcerations and varices 11, 13, 14 . The most significant consequence of VTE is massive PE, which may end by sudden death in 20% of cases, leaving no time for any medical intervention 10 . Discovering such a state could be a diagnostic problem, but it was proven to be worth the effort, because appropriate diagnosis, prevention and treatment could reduce mortality rate from 20% to 0.7% 15 . The goal of this article was to analyse the risk factors for VTE in pregnancy and puerperium, and medicational options and protocols for thromboprophylaxis.
Characteristics of venous thromboembolism in pregnancy and puerperium
During pregnancy approximately 80% of VTE are DVT and 20% are PE 6, 8, 9, 16 . Two thirds of pregnancyrelated DVTs occur before, and one third after the delivery 1, 4, 17 . Considering the fact that postpartal period lasts much shorter than antepartal (6 : 40 weeks respectively), we conclude that the risk of developing DVT is approximatelly 3 times higher in the postpartum period. The same holds for PE 43 60% develops in the first 4 6 weeks after the delivery 8, 9, 13, 18 . Pregnancy itself is an independent risk factor for VTE (4 5 times higher risk than in non-pregnant women of similar age) and in puerperium the risk is even higher (from 15 up to 60 times) 1, 6, 8, 9, 11, [19] [20] [21] . Pregnancy is associated with prothrombotic state, which is one of physiologic changes meant to protect pregnant women from peripartal haemorrhage, which is still the main cause of maternal mortality in the developing world 9, 16, 21 . Beginning early in pregnancy, there is an increase of procoagulant factors and a decrease in the level of protein S, and a resistance to activated protein C 8, 9, 11, 13 . Two other elements of Virchow's triad are also present. Venous stasis is a consequence of mechanical obstruction of blood flow by gravid uterus, and of hormonally induced decrease in venous tone, resulting in slower blood flow in lower limbs. Endothelial damage is a result of tearing and distension during delivery 8, 9, 11, 18 . One of the characteristics of pregnancy-related DVT is 80 90% occurence in the left leg (compared to 55% in nonpregnant patients), which is a consequence of the anatomy of the left common iliac vein It is believed today that VTE is a convergence of underlying genetic predisposition thrombophilia, and of acquired precipitating causes 12 .
Inherited thrombophilias
Factor V Leiden (FVL) is thrombophilia with high prevalence in general population; in 20 46% of pregnant women with VTE the heterozygot for FVL is found 11, 13 . FVL is a single base pair mutation on a factor V gene that makes it resistant to inactivation by the activated protein C complex. This results in a loss of one of the normal protective antithrombotic mechanisms 25 and increases the risk of VTE 41 times in homozygous and 2 16 times in heterozygous patients 8, 11 . In the non-pregnant state, FVL deficiency equally leads to DVT and PE; in pregnancy DVT dominates, probably because FVL is here associated with a more adherent and stable thrombus, due to increased local thrombin generation, which reduces the probability of embolisation 11 . Mutation on a 20210 nucleotide on a prothrombin gene (G20210A) increases plasma prothrombin concentration, with consequent increased risk of myocardial infarct, cerebral venous thrombosis and VTE 25 . In pregnancy it increases the risk of VTE 3 10 times, and it is found in 20% of gestational VTE 8 . Hyperhomocysteinemia is rare in pregnancy, because of pregnancy-related physiological reduction in homocysteine 13, 26 . Protein S, protein C and antithrombin (AT III) deficiency are less common. The prevalence of AT III deficiency in women with pregnancy-associated VTE is 1 19%, the prevalence of protein C deficency 2-14%, and for protein S deficiency 1-12% 11 . The risk of pregnancy-associated VTE in cases of AT III deficiency type I (quantitative) was found to be 1 : 2.8, and for type II (qualitative) 1 : 42 patients with no previous history of VTE. This leads to more aggressive thromboprophyllaxis in pregnancy for AT III deficient patients 27 . AT III deficiency mainly leads to DVT, often in uncommon regions: kidney, retina, mesenterium, upper limbs, vena cava. In cases of protein C and protein S deficiency the risk of VTE is increased 2 4 and 3 fold respectively 8 . One should keep in mind that there are numerous conditions that influence thrombophilia screen: liver disease, as well as pregnancy itself, lower protein C and S levels; severe infection, nephrotic syndrome, massive thrombosis lower AT III level, so laboratory results should be carefully interpreted 28 . 4G/5G sequence polymorphism in PAI 1 (plasminogen activator inhibitor 1) gene promoter: PAI 1 is produced by endothelial, smooth muscle, liver cells and platelets and represents a principal inhibitor of fibrinolysis. Its plasma level steadily increases during pregnancy and at term it is 3 fold higher than in the non-pregnancy state; there is also PAI 2, produced by placenta 29, 30 . They both contribute to hypercoagulable state seen in every pregnancy. DVT risk could be augmented by the presence of mutation changes on 4G/5G base-pair region on PAI 1 gene, that modulate PAI 1 synthesis. 4G allele is too small to bind gene transcriptional repressors, so 4G/4G allele homozygosity leeds to 3 5 fold higher level of circulating PAI 1, and was associated with metabolic syndrome and a greater risk for cardiovascular and thrombotic disease [30] [31] [32] [33] [34] [35] . Sartori et al. 36 report a greater risk of thrombosis both in sympthomatic thrombophilic patients (OR 2.85, 95% CI 1.26 4.46) and idiopatic DVT patients (OR 3.1, 95% CI 1.26 7.59) with 4G/4G phenotype. In pregnancy, this disorder is frequently associated with FVL mutation, or antiphospholipid syndrome, or protein S deficiency, further predisposing these women to thrombosis as well as implantation failure 30, 32, 35, 37, 38 . It should be mentioned that the inherited thrombophilias are involved in development of other obstetrics complications associated with insufficient fetomaternal circulation and failure of implantation, such as early and late abortion, preeclampsia, placental abruption, fetal intrauterine growth restriction (IUGR) 25, [39] [40] [41] . Inherited thrombophilias are proven to be the cause of gestational VTE in 20 50% 25 and represent a danger that should not be underestimated 2, 3, 7, 16 . On the other hand, thromboprophylaxis itself could be risky for both fetus and mother; so one should be rational, meaning that one should estimate the risk and identify patients who really need thromboprophylaxis. Estimated risk of pregnancy-associated VTE in thrombophylic women without prior VTE (odds ratio) is 34.4 for FVL homozygosity, 8.32 for heterozygosity; 26.6 for homozygous prothrombin gene mutation 6.8 for heterozygous; 4.76 for antithrombin, 4.76 for protein C and 2.19 for protein S deficiency 9, 20, 26, 42, 43 (Table 1) . Based on these estimates, in cases of thrombophilia with no prior VTE the American College of Chest Physicians (ACCP) recommends antepartal low-molecular weight heparin (LMWH) prophylaxis only for homozygous women with FVL or prothrombin gene mutations, who have a positive family history for VTE 26, 43, 44 . At the moment there are no proofs in the literature that justify universal screening for thrombophilias in pregnancy.
It is recommended that screening should be selective, conducted in patients with a history of VTE, with first and second degree relatives who had VTE, as well as those with complications in previous pregnancies 45 .
Acquired risk factors
The most important among acquired risk factors is the previous VTE 3, 4, 18, 21 . Pregnancy itself amplifies the risk of VTE recurrence 3.5 fold 7, 9, 11, 12, 20 . In their prospective study on 125 pregnant women with prepregnancy VTE Brill-Edvards et al. 46 using only postpartal VTE prophylaxis, have shown that the absolute recurrence rate was 2.4%. No recurrence was observed in 44 women who had no evidence of thrombophilia, and who had experienced VTE related to a temporary risk factor. This study challenged the assumption that all women with the history of VTE should receive antepartal thromboprophylaxis. In their retrospective cohort study Roeters Van Lennep et al. 47 tried to evaluate effectiveness of low doses of LMWH prophylaxis in women with intermediate risk for VTE (during six weeks postpartum) and with high risk (during entire pregnancy and six weeks postpartum). They had 5.5% VTE recurrence, all in the high risk group and concluded that a low dose LMWH might not be sufficient in the high risk pregnant patients. Stratta et al. 48 emphasize that it is important to estimate the risk properly and determine the appropriate LMWH dose and dosing regimen (once/twice daily) for each risk level. Thus, although available data from clinical trials are not completely uniform, it can be concluded that even though pregnancy increases the risk of VTE recurrence, antepartal prophylaxis is not routinely recommended. It should be applied in patients with idiopathic first VTE episode, in the presence of an underlying thrombophilia, in women who used oral contraceptives 45 . Puerperium is by all means a period that demands prophylaxis and, in cases of higher risk, even augmentation of the usual doses. Phabinger et al. 49 studied the risk of VTE recurrence in pregnancy without antepartal thromboprophylaxis and found that antepartal risk was 6.2%, and postpartal 6.5% 41 . Antiphospholipid-antibody syndrome (APLA) leads to recurrent artherial and venous thrombosis, as well as other pregnancy complications (spontaneous abortion, preeclampsia, IUGR) 21 . APLA presence affects almost all haemostatic factors, provoking thrombotic diathesis, complement activation, inflammation, disbalance of angiogenic factors and disturbance of normal fetoplacental development. Anticomplemental and vasomodulatory action of heparin make this drug irreplaceable in prevention of APLA complications in pregnancy 50 . ACCP recommends antepartum administration of heparin combined with a low dose aspirin (75 100 mg/day) 26 . After Caesarean section the prevalence of clinically significant VTE is 0.9%. We should consider thromboprophylaxis in women older than 35 years, with body mass over 90 kg, with present infection, varicous veins, gestational hypertension, multiparity, VTE in anamnesis, emergency Caesarean section or hysterectomy after Caesarean section 12 . Assisted reproductive treatment (ART) also represents a risk factor for VTE, especially when associated with ovarian hyperstimulation syndrome (OHSS). It is believed that this is a consequence of 10 fold increased estradiol levels by hormonal stimulation, increased coagulation factors concentration and decreased fibrinolysis. Thrombosis typically occurs between the 7th and 10th week of gestation, located in about 60% in upper limbs, neck and head veins 7, 12 . In cases of pregnancies after ART routine thromboprophylaxis is not recommended, but in cases of OHSS, LMWH prophylaxis is recommended after a resolution of the syndrome 26 . Preeclampsia was found to increase three fold the risk of VTE in the third trimester and postpartum. Preeclampsia is a consequence of maternal immunologic maladaptation to fetal and placental tissue, resulting in generalised endothelial insufficiency, disturbed eikosanoid metabolism, lipid peroxidation, inflammation, activation of complement system and coagulation cascade. There are numerous studies that connect inherited thrombophilias and preeclampsia [51] [52] [53] [54] [55] . Heparin and low-dose aspirin are used to treat procoagulant and inflammatory disorders in such situations 51, 55, 56 . Among other risk factors (advanced age, parity, maternal comorbidity etc) maternal obesity should not be forgotten, because it is a global epidemic nowadays 57 . Hypercoagulability, venous stasis and endothelial disfunction in pregnancy are exacerbated by obesity. Body mass index (BMI) over 30 kg/m 2 increases the risk for VTE 1.5 5.3 fold 5, 7 , so it is recommended that all women with morbid obesity (BMI over 40 kg/m 2 ) should receive seven days postpartal LMWH prophylaxis 4, 45, 57 . In cases of increased body mass higher LMWH doses may be needed, but dose estimation according to actual body weight could lead to overdosing. In such cases it would be wiser to use lean body weight for appropriate dosing, with plasma anti-factor Xa level monitoring 57 . We thought it would be interesting to mention a study of Jakobsen et al. 58 , who investigated ante-and postpartal factors for development of VTE. To antepartal risk factors already mentioned in the literature (age older than 35 years, multiple pregnancy, blood group A, obesity, smoking), they added pregnancy after assisted reproductive treatment, gestational diabetes, nulliparity, weight gain in pregnancy less than 7 kg. The authors found that besides the age over 35 years, operative delivery, hypertension, blood group A, postpartal risk factors were emergency Caesarean section, haemorrage or infection, preeclampsia, IUGR, assisted reproductive treatment, smoking. Immobilisation, especially in combination with higher BMI, represents an important risk factor ante-and postpartaly 4, 58 .
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Medication options for thromboprophylaxis in pregnancy and puerperium
The goal of thromboprophylaxis is to provide VTE protection with minimal side effects for the mother and no effects on the fetus. Although today we have a huge choice of anticoagulant and antiplatelet agents, heparin is still the anticoagulant of choice for VTE prophylaxis and treatment in pregnancy 6, 16, 26, 45, 59 . Heparin, neither unfractionated (UFH) nor LMVH, crosses the placenta; it is not secreted in breast milk, it is not teratogenic and there is no evidence of risk of fetal haemorrhage. Currently, LMWHs have replaced UFH as the first choice anticoagulant 26, 27, 45, [59] [60] [61] [62] [63] . LMWHs are at least as effective as UFH, but produce more predictable anticoagulant response due to better bioavailability (90 100% after subcutaneous administration), longer half life (4 6 h), dose-independent renal clearance, decreased affinity for heparin-binding proteins, endothelial cells and macrophages 6, 7, 48 . Effective anticoagulation can be achieved by subcutaneous application of LMWH once daily, with no need for routine laboratory monitoring of anti-factor Xa activity in plasma.
Nevertheless, in certain situations LMWH dose adjustment is necessary and that demands anti-Xa level assessment. Pregnancy changes LMWH pharmacokinetics. Together with the increase of cardiac output and plasma volume, glomerular filtration rate progressively increases from the first trimester; at term it is 50 60% higher than in the non-pregnant state, with increased volume of distribution and drug clearance 48 . This could result in subprophylactic antiXa level in 26% of patients 6, 7, 48 . Anti-Xa activity is inversely related to body weight, so LMWH doses should be modified in cases of maternal obesity 14, 57 . On the other hand, in patients with renal disease and creatinine clearance below 30 mL/min, standard LMWH doses may lead to accumulation of heparin, higher anti-Xa level and increased risk of bleeding. In such cases LMWH dose should be reduced (based on anti-Xa level) or UFH used instead 18, 26, 64 . According to dose regimen, LMWH doses used for VTE prophylaxis in pregnancy could be prophylactic (for example dalteparin 5000 units or enoxaparine 40 mg, subcutaneously every 24), intermediate (dalteparin 5000 units or enoxaparine 40 mg, subcutaneously every 12) or adjusted (dalteparin 200 units/kg once daily or 100 units/kg/12 h; enoxaparin 1 mg/kg/12 h) 26, 43, 45 (Table 2 ).
More favorable anti-Xa/IIa ratio of LMWHs comparing to UFH (2 4 : 1), significantly lowers the risk of haemorrhage (1 2%, and mostly related to obstetric causes) 1, 26, 63 . Prolonged use of UFH increases risk of osteoporosis, with 2 3% incidence of osteoporotic fractures and significant reduction in bone density in up to 30% of patients 26, 64 . After LMWH therapy bone mass reduction equals physiological bone mass reduction in pregnancy 1, 13, 22, 26, [65] [66] [67] [68] . Heparin induced thrombocytopenia with or without thrombosis (HIT/HITT), carries 1 3% risk with UFH and is 10 fold less frequent after LMWH than after UFH therapy 26, 66 . The risk is indeed very low in obstetric patients receiving LMWH, so routine platelet monitoring is not recommended 7, [68] [69] [70] [71] . Cutaneous allergic reactions (delayed type 4 hypersensitivity reaction) occur more frequently in pregnancy (1.8 29%) than in general population, but they are seldom severe 26 . This problem may be resolved by switching to another LMWH preparation or danaparoid or fondaparinux 1, 72 . One further advantage of LMWH over UFH is significantly less procoagulant "rebound effect" after withdrawal of the therapy 73, 74 . At the time of delivery LMWH advantages may became disadvantages: anticoagulant effect can persist more than 12 h after the last dose and protamin sulfate cannot neutralise its action completely in case of need (anti-Xa effect remains), so peripartal haemorrhage can occur 14, 64, [75] [76] [77] [78] . LMWH discontinuation is recommended 24 h before induction of labour or planned Caesarean section 7, 26, 78 . High risk patients can be converted to intravenous UFH (aPTT monitoring required), which can than be stopped 4-6 h before the induction of labour 1, 6, 26, 76 . If haemostasis is adequate, thromboprophylaxis could be continued 6 12 h after vaginal and 12 24 h after Caesarean delivery 1, 4, 7, 9, 26, 45, 76, 78 . With the increased use of neuraxial anesthesia in labor, we should be aware of its possible complicationspinal haemathoma with subsequent paraplegia 79 . In order to reduce the risk of such event, epidural catheter can be safely inserted 12 h after prophylactic and 24 h after therapeutic LMWH dose; it can be remowed 12 h after the last dose 4, 7, 16, 77 . Anticoagulation can be restarted 4-24 h after catheter removal 8, 9, 20, 27, 45, 64, 77, 80 . Warfarin crosses the placenta and has proven teratogenity 6, 26, 45 . Coumarin embriopathy is dose-dependent (more than 5 mg/24 h) and occurs in 5% of cases exposed between the 6th and 12th gestational weeks, so in this period warfarin is contraindicated 45 . The first trimester warfarin exposure leads to abortion; later exposure may be associated with fetal haemorrhage, CNS abnormalities, child's mental retardation and increased risk of placental abruption and postpartum haemorrhage 9, 13, 26 . The use of warfarin in pregnancy can be justified in case of women with mechanical heart valves, where benefit overweighs the risk 6, 26 . In all the other cases it should be replaced by heparin as soon as patient finds that she is pregnant 26 . Since it is not secreted in breast milk, warfarin is safe to use during breastfeeding, although it requires close monitoring 6, 13, 26, 45 . Dextran is today practically abandoned in obstetrics, because of the risk of anaphyllaxis associated with uterine hypertonus, profound fetal distress and even death 45 . Danaparoid -experience is limited with its use; crossing the placenta and secretion in breast milk were not found, but still its only indication in pregnancy for the time being is complication of heparin therapy 14, 26, 45 . In the newest ACCP recommendations danaparoid is suggested over lepirudin or fondaparinux for treatment of HIT during pregnancy 26, 81 . Fondaparinux during its use 10% of anti-Xa activity in mother's plasma was found in umbilical blood; although there were no fetal complications, it is still early to conclude that fondaparinux is safe for use in pregnancy 9, 26, 45, 72 . It has been used in pregnant patients with HIT 71 . Graduated elastic compression stockings (GCS) is recommended when LMWH is contraindicated, or in combination with LMWH after Caesarean section in the presence of several risk factors, or in pregnant women travelling by air longer than 4 h 59, 82 . Using GCS also reduces the risk of postthrombotic syndrome 2 . During lactation warfarin, LMWH, UFH, danaparoid and hirudin are allowed; pentasacharides (fondaparinx) are not recommended 26 .
Recommendations for venous thromboembolism prophylaxis in pregnancy and puerperium
In order to diminish the risk of VTE in pregnancy/puerperium all women should undergo assessment of the risk factors for VTE in early pregnancy or, ideally, before pregnancy 6, 18, 45, 83 . This assessment should be repeated during pregnancy, before and after the labor. Based on this assessment an thromboprophylactic plan should be made with haemathologist or other experts if needed 2, 4, 26, 45 .
Patients with very high VTE risk are those with previous VTE on the long term warfarin/AT III deficiency/APLA with previous VTE. For them, antepartal high dose LMWH and at least 6 weeks postpatral LMWH or warfarin are recommended 45 . Women with previous recurrent or unprovoked or estrogen provoked VTE, previous VTE with thrombophilia or with family history of VTE and those with asymptomatic thrombophilia (homozygous for FVL or prothrombin gene mutation) with positive VTE family history, are in high VTE risk. For them antepartal and 6 weeks postpartal LMWH prophylaxis is recommended 45 . Women with intermediate VTE risk are those with single previous VTE provoked by transient risk factor no longer present, without thrombophilia, family history, or other risk factors and those with mild asymptomatic thrombophilia or with medical comorbidities, or BMI over 40 kg/m 2 . In this group consider antepartal LMWH prophylaxis and apply 7 days 6 weeks postpartal prophylaxis 45 . Lower-risk group consists of women older than 35 years, with BMI higher than 30 kg/m 2 , or systemic infection, or OHSS, preeclampsia, ART, immobility, varicous veins, multiple pregnancies, operative delivery, postpartal blood loss more than 1,000 mL. If there is a combination of more than three of those risk factors antepartum and more than two postpartum, LMWH prophylaxis is given antepartum and at least 7 days postpartum 45 . If there is less than three factors ante-and two postpartum, early mobilization and rehidratation are sufficient 45 .
Recommendaions for thromboprophylaxis in pregnancy/puerperium according to risk assessment are summarised in the Table 3 .
We should emphasize that those recommendations are not meant to dictate the definite course of management; they should, of course, be adjusted to individual patient.
Conclusion
Venous thromboembolism although relatively rare in pregnancy, is a serious problem with hard consequences, so it deserves and demands medical attention. The fact that recognizing risk factors and performing adequate prophylaxis significantly reduces the incidence of venous thromboembolism, obligates us to an active relation towards this problem. 
